Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations

    January 2024 in “ Curēus
    Philip A Holubeck, Andrew C Eksi, K Gillett, James O’Hara, Daniel J McGoldrick, D. Clayton Brown, Alec McCarthy
    Image of study
    TLDR Clinicians should use social and prescription data to track trends in performance-enhancing drug use.
    This study investigates the trends in interest for performance-enhancing drugs (PEDs) and related ancillary compounds, highlighting a significant rise in interest for selective androgen receptor modulators (SARMs) like RAD-140, while interest in anabolic steroids and post-cycle therapies remains stagnant or decreases. The authors suggest using social and prescription data as proxies to help clinicians better understand and adapt to these trends, given the lack of clinically relevant data and evidence-based approaches for monitoring PED use and its adverse effects.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 216 results

      community The most nuclear stack possible

      in Satire  38 upvotes 4 months ago
      A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

      community Summary of future treatments from 2020

      in Chat  52 upvotes 2 weeks ago
      Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

      community So we’re just ok with taking a research chemical now?

      in Treatment  181 upvotes 4 years ago
      The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

    Similar Research

    5 / 1000+ results